Modeling the cost-effectiveness of galantamine for mild to moderately severe alzheimer's disease in Korea

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Suh, Guk Hee ^a  

^a Hallym University Medical Center   (South Korea)

Author keywords

Alzheimer; Cost effectiveness; Galantamine; Korea

Indexed keywords

GALANTAMINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG USE; HUMAN; MONEY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SOUTH KOREA;

EID: 72149114594     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00627.x     Document Type: Article

References (41)

1. Suh GH, Kim JK, Cho MJ. Community study of dementia in the older Korean population. Aust N Z J Psychiatry 2003 37 : 606 612.
2. Suh GH. Dementia in Korea: trend and projection. J Korean Geriatr Psychiatry 2002 6 : 28 35.
3. Galasko D, Edland SD, Morris JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease over 3 years. Neurology 1995 45 : 1451 1455.
4. Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996 277 : 728 738.
5. Raskind M, Peskind ER, Truyen L, et al. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004 61 : 252 256.
6. Pirttilä T, Wilcock G, Truyen L, et al. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004 11 : 734 741.
7. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with "advanced moderate" Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003 15 : 79 87.
8. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 54 : 2261 2268.
9. Suh GH, Jung HY, Lee CU, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Ther 2004 26 : 1608 1618.
10. Suh GH, Jung HY, Lee CU, et al. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. J Korean Med Sci 2008 23 : 10 17.
11. Suh GH, Knapp M, Kang CJ. The economic costs of dementia in Korea, 2002. Int J Geriatr Psychiatry 2006 21 : 722 728.
12. Suh GH. Predictors of mortality in an aging community-based cohort in Korea. Psychogeriatrics 2006 6 : 10 18.
13. Suh GH, Jung HY, Lee CU, et al. Effect of the Apolipoprotein E4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2006 21 : 33 9.
14. Park S, Lee JY, Suh GH, Cho MH. Mortality rates and risk factors in community-based dementia patients. J Korean Geriatr Psychiatry 2007 11 : 25 8.
15. Lee JY, Chang SM, Jang HS, et al. Illieracy and the incidence of Alzheimer's disease in the Yonchon County survey, Korea. Int Psychogeriatr 2008 20 : 976 985.
16. Beecham J, Knapp M. Costing psychiatric interventions. In : Thornicroft G, ed. Measuring Mental Health Needs (2nd ed.). London : Gaskell, 2001.
17. Wimo A, Mastey V, Winblad B. Evaluation of the health care resource utilization and caregiver time in antidementia drug trials-a quantitative battery. In : Wimo A, Jonsson B, Karlsson G, et al., eds. Health Economics of Dementia (1st ed.). Chichester : John Wiley & Sons, 1998.
18. Hyoplus. Hourly wage. Available from: http://www.koreanursing.co.kr/ service/service-gasa.php [Accessed March 20, 2006 BH, Sunwoo D, Choi HM. Report on the Introduction of Public Long-Term Care Insurance for the Elderly in Korea. Seoul : Korea Institute of Health and Social Affairs, 2001.
19. National Health Insurance Corporation. 2002 National Health Insurance Statistical Yearbook. Seoul : National Health Insurance Corporation, 2003.
20. Ministry of Health and Welfare. Guideline for Health and Welfare Program for the Elderly. Kwacheon : Ministry of Health and Welfare, 2004.
21. June KJ, Park JY. Cost-effectiveness analysis of home health care program for cerebrovascular accident patients. J Korean Community Nurs 2001 12 : 22 31.
22. Kang IO, Park JY, Lee YK, et al. A Report for the Socioeconomic Costs of Dementia Using Health Utilization of Dementia Patients [Research Report 2005-12 Seoul : National Health Insurance Corporation, 2005.
23. Bowie P, Branton T, Holmes J. Should the Mini-Mental State Examination be used to monitor dementia treatments? Lancet 1999 354 : 1527 1528.
24. Davey RJ, Jamieson S. The validity of using the minimental state examination in NICE dementia guidelines. J Neurol Neurosurg Psychiatry 2004 75 : 343 344.
25. Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001 57 : 964 971. (Pubitemid 32880187)
26. Suh GH, Shah A. A review of epidemiological transition in dementia - cross-national comparisons of the indices related to Alzheimer's disease and vascular dementia. Acta Psychiatr Scand 2001 104 : 4 11.
27. Suh G.H, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 2004 19 : 817 824.
28. Suh GH, Yeon BK, Shah A, Lee JY. Mortality in Alzheimer's disease: a comparative prospective Korean study in community and nursing home. Int J Geriatr Psychiatry 2005 20 : 26 34.
29. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy years equivalents. Med Decis Making 1989 9 : 142 149.
30. Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer's disease. A cross-sectional study of patients and caregivers. Med Care 1999 37 : 27 32.
31. National Institute for Clincal Excellence. Technology appraisal guidance number 19: donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease. Available from: http://www.nice.org.uk/page.aspx?0=245908 [Accessed January 3, 2008 C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2005 23 : 1271 1282.
32. Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD) Galantamine treatment in Canada. Neurology 2001 57 : 972 978. (Pubitemid 32880188)
33. Caro JJ, Salas M, Ward A, et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in The Netherlands. Dement Geriatr Cogn Disord 2002 14 : 84 9.
34. Aneshensel CS, Pearlin LI, Levy-Storms L, et al. The transition from home to nursing home Mortality among people with dementia. J Gerontol B Psychol Sci Soc Sci 2000 55B : S152 62.
35. Wallin AK, Gustafson L, Sjögren M, et al. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004 18 : 197 206.
36. Lopez OL, Becker JT, Wisniewsk S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzeimer's disease. J Neurol Neurosurg Psychiatry 2002 72 : 310 314.
37. López-Pousa S, Olmo JG, Franch JV, et al. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine. Age Ageing 2006 35 : 365 371. (Pubitemid 43941803)
38. Ott BR, Lapane KR. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002 50 : 35 40.
39. Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatr Pharmacother 2005 3 : 1 7.
40. Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000 44 : 236 241.
41. Suh GH. Mental health care in South Korea. Int Psychiatry 2005 7 : 10 12.